search
Back to results

Extending Preservation and Assessment Time of Donor Lungs Using the Toronto EVLP System™ at a Dedicated EVLP Facility

Primary Purpose

Lung Disease

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Toronto EVLP System™
Sponsored by
Lung Bioengineering Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Lung Disease focused on measuring Ex Vivo Lung Perfusion, EVLP, Lung Transplant, Lung Transplantation, Toronto EVLP System™, PERFUSIX

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Subject Inclusion Criteria:

In order to be eligible to participate in this study, an individual must meet all of the following criteria:

  • Male or female patients
  • All patients, 18 years of age or older
  • Patient already on or added to the active waiting list for a single or bilateral lung transplant
  • Patient or patient's representative provides informed consent for participation in the study at the time of study commencement or time of listing for transplant
  • Patient or patient's representative reconfirms informed consent for the study on the day of lung transplant

Subject Exclusion Criteria:

A subject who meets any of the following criteria will be excluded from participation:

  • Patients listed for same-side lung re-transplantation
  • Patients listed for multiple organ transplantation including lung and any other organ
  • Patients listed for live donor lobar transplant
  • Patients with HIV, active Hepatitis B/C, or Burkholderia Cepacia
  • Patients not initially consented into the study prior to the time of lung transplant
  • Patients in the ICU at the time of initial lung offer requiring mechanical ventilation, ECMO or other Extracorporeal life support (ECLS).

Donor Lung Inclusion Criteria for EVLP Assessment:

The donor lung must meet at least one of the following criteria to proceed with EVLP:

  • At the time of the clinical evaluation, the donor PaO2/FiO2 < 300 mmHg
  • Donor received ≥ 10 units of blood transfusions
  • Donation after Cardiac Death (DCD) donor
  • Expected cold ischemic time > 6 hours
  • Donor age ≥ 55 years old
  • Study Center Investigator requires additional assessment ex vivo and/or extended preservation time

Donor Lung Exclusion Criteria for EVLP Assessment:

The donor lung is excluded from EVLP if at least one of the following criteria have been met:

  • The donor lung has confirmed pneumonia and/or persistent purulent secretions identified via bronchoscopy
  • Non-persistent purulent secretions that do not clear by hour 3 on EVLP
  • The donor lung has confirmed evidence of aspiration
  • The donor lung has significant mechanical lung injury or trauma
  • The cold ischemic time, starting at donor aortic cross clamp/ initial flush (CIT-1), required to transport the lung from the donor site to start of the EVLP procedure at SPONSOR's facility > 10 hours

EVLP Lung Inclusion Criteria for Transplantation:

The donor lung must meet each of the following conditions post-EVLP for transplant suitability consideration by the Study Center Investigator:

  • PvO2/FiO2 ≥ 350 mmHg at final EVLP evaluation time period
  • and < 15% increase from baseline value (defined as the first hour collection point) to final value of pulmonary vascular resistance (PVR)
  • and < 15% increase from baseline value to final value of peak airway pressure (PawP)
  • and < 15% decrease from baseline value to final value of static lung compliance (Cstat)
  • and the total preservation time (TPT) does not exceed the following:

    • the initial CIT-1 time from donor to EVLP > 1 hour and ≤ 10 hours
    • the EVLP time > 3 hours and ≤ 6 hours
    • the second CIT-2 from EVLP cool down to beginning of recipient implantation must be > 1 hour and ≤ 6 hours for the first lung
    • the second CIT-2 from EVLP cool down to beginning of recipient implantation must be > 1 hour and ≤ 10 hours for the second lung
  • and Study Center Investigator deems lung function suitable for intended subject

EVLP Lung Exclusion Criteria for Transplantation:

The donor lung is excluded from transplant inclusion if at least one of the following criteria have been met:

  • PvO2/FiO2 < 350 mmHg at final EVLP evaluation time period
  • or ≥ 15% increase from baseline value to final value of pulmonary vascular resistance (PVR)
  • or ≥ 15% increase from baseline value to final value of peak airway pressure (PawP)
  • or ≥ 15% decrease from baseline value to final value of static lung compliance (Cstat)
  • or TPT exceeds any of the following conditions:

    • CIT-1 < 1 hour or > 10 hours
    • EVLP < 3 hours or > 6 hours
    • CIT-2 < 1 hour or > 6 hours for first lung or > 10 hours for second lung
  • or Study Center investigator deems lung function unsuitable for intended subject

Sites / Locations

  • Mayo Clinic Jacksonville
  • Loyola University Medical Center
  • University of Maryland Medical Center
  • University of Michigan Health System
  • Duke University Health System
  • Cleveland Clinic
  • UPMC
  • Inova Fairfax Medical Campus

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Experimental

No Intervention

Arm Label

EVLP Double Lung Group

EVLP Single Lung Group

Control Group

Arm Description

Toronto EVLP System™ administered to double lungs.

Toronto EVLP System™ administered to single lungs.

Those patients receiving a single or double lung via conventional transplant.

Outcomes

Primary Outcome Measures

Count of Participants With Primary Graft Dysfunction (PGD), Grade 3
Primary Graft Dysfunction is a scale published by the International Society of Heart and Lung Transplantation that uses patient oxygenation and radiographic results to score patients on a 0 (zero) to 3 (three) scale, with 3 being the most significant dysfunction.
Count of Participants Surviving
The number of participants that survived to 30 days post-transplant.

Secondary Outcome Measures

PGD Score
PGD Score (0-3) at 0, 24, 48 & 72 hours post-transplant
ICU Length of Stay
Total Lung Preservation Time (TPT)
Time to First Extubation
Hospital Length of Stay

Full Information

First Posted
September 4, 2014
Last Updated
November 16, 2020
Sponsor
Lung Bioengineering Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT02234128
Brief Title
Extending Preservation and Assessment Time of Donor Lungs Using the Toronto EVLP System™ at a Dedicated EVLP Facility
Official Title
A Phase 2, Multicenter, Open-label Study to Measure the Safety of Extending Preservation and Assessment Time of Donor Lungs Using Normothermic Ex Vivo Lung Perfusion and Ventilation (EVLP) as Administered by the SPONSOR Using the Toronto EVLP System™
Study Type
Interventional

2. Study Status

Record Verification Date
November 2020
Overall Recruitment Status
Completed
Study Start Date
July 18, 2015 (Actual)
Primary Completion Date
November 21, 2018 (Actual)
Study Completion Date
November 7, 2019 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Lung Bioengineering Inc.

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
This is a safety study to compare the safety of receiving a lung treated with the Toronto EVLP System™ by SPONSOR in SPONSOR's dedicated facility against standard lung transplantation.
Detailed Description
Human donor lungs allocated to a participating study transplant center (Study Center) for a specific recipient and meeting study EVLP donor lung inclusion/exclusion criteria will be assessed by SPONSOR for inclusion into the study. Upon retrieval, donor lung(s) will be packaged and transported on ice to the SPONSOR's EVLP facility in Silver Spring, Maryland, no differently than when lungs are recovered, packaged, and transported to any transplant center for implantation. The EVLP procedure will be performed by Certified Ex Vivo Lung Specialists using the Toronto EVLP System™ for up to 6 hours, collecting and relaying lung function assessment data hourly or as requested by the Study Center transplant surgeon. Additionally, the Study Center surgeon will have the capability to evaluate lung function data and monitor the procedure remotely through a dedicated video link. Upon acceptance of an EVLP donor lung by the Study Center, the single lung or lung block is cooled down by the Toronto EVLP System™ to 10 degrees C. Thereafter, perfusion and ventilation are stopped and the lung is prepared for hypothermic storage and transport to the accepting Study Center.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Lung Disease
Keywords
Ex Vivo Lung Perfusion, EVLP, Lung Transplant, Lung Transplantation, Toronto EVLP System™, PERFUSIX

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
118 (Actual)

8. Arms, Groups, and Interventions

Arm Title
EVLP Double Lung Group
Arm Type
Experimental
Arm Description
Toronto EVLP System™ administered to double lungs.
Arm Title
EVLP Single Lung Group
Arm Type
Experimental
Arm Description
Toronto EVLP System™ administered to single lungs.
Arm Title
Control Group
Arm Type
No Intervention
Arm Description
Those patients receiving a single or double lung via conventional transplant.
Intervention Type
Device
Intervention Name(s)
Toronto EVLP System™
Intervention Description
Extending preservation and assessment time of donor lungs using the Toronto EVLP System
Primary Outcome Measure Information:
Title
Count of Participants With Primary Graft Dysfunction (PGD), Grade 3
Description
Primary Graft Dysfunction is a scale published by the International Society of Heart and Lung Transplantation that uses patient oxygenation and radiographic results to score patients on a 0 (zero) to 3 (three) scale, with 3 being the most significant dysfunction.
Time Frame
72 Hours
Title
Count of Participants Surviving
Description
The number of participants that survived to 30 days post-transplant.
Time Frame
30 Days
Secondary Outcome Measure Information:
Title
PGD Score
Description
PGD Score (0-3) at 0, 24, 48 & 72 hours post-transplant
Time Frame
0, 24, 48 & 72 Hours
Title
ICU Length of Stay
Time Frame
30 Days
Title
Total Lung Preservation Time (TPT)
Time Frame
72 Hours
Title
Time to First Extubation
Time Frame
Days
Title
Hospital Length of Stay
Time Frame
Days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Subject Inclusion Criteria: In order to be eligible to participate in this study, an individual must meet all of the following criteria: Male or female patients All patients, 18 years of age or older Patient already on or added to the active waiting list for a single or bilateral lung transplant Patient or patient's representative provides informed consent for participation in the study at the time of study commencement or time of listing for transplant Patient or patient's representative reconfirms informed consent for the study on the day of lung transplant Subject Exclusion Criteria: A subject who meets any of the following criteria will be excluded from participation: Patients listed for same-side lung re-transplantation Patients listed for multiple organ transplantation including lung and any other organ Patients listed for live donor lobar transplant Patients with HIV, active Hepatitis B/C, or Burkholderia Cepacia Patients not initially consented into the study prior to the time of lung transplant Patients in the ICU at the time of initial lung offer requiring mechanical ventilation, ECMO or other Extracorporeal life support (ECLS). Donor Lung Inclusion Criteria for EVLP Assessment: The donor lung must meet at least one of the following criteria to proceed with EVLP: At the time of the clinical evaluation, the donor PaO2/FiO2 < 300 mmHg Donor received ≥ 10 units of blood transfusions Donation after Cardiac Death (DCD) donor Expected cold ischemic time > 6 hours Donor age ≥ 55 years old Study Center Investigator requires additional assessment ex vivo and/or extended preservation time Donor Lung Exclusion Criteria for EVLP Assessment: The donor lung is excluded from EVLP if at least one of the following criteria have been met: The donor lung has confirmed pneumonia and/or persistent purulent secretions identified via bronchoscopy Non-persistent purulent secretions that do not clear by hour 3 on EVLP The donor lung has confirmed evidence of aspiration The donor lung has significant mechanical lung injury or trauma The cold ischemic time, starting at donor aortic cross clamp/ initial flush (CIT-1), required to transport the lung from the donor site to start of the EVLP procedure at SPONSOR's facility > 10 hours EVLP Lung Inclusion Criteria for Transplantation: The donor lung must meet each of the following conditions post-EVLP for transplant suitability consideration by the Study Center Investigator: PvO2/FiO2 ≥ 350 mmHg at final EVLP evaluation time period and < 15% increase from baseline value (defined as the first hour collection point) to final value of pulmonary vascular resistance (PVR) and < 15% increase from baseline value to final value of peak airway pressure (PawP) and < 15% decrease from baseline value to final value of static lung compliance (Cstat) and the total preservation time (TPT) does not exceed the following: the initial CIT-1 time from donor to EVLP > 1 hour and ≤ 10 hours the EVLP time > 3 hours and ≤ 6 hours the second CIT-2 from EVLP cool down to beginning of recipient implantation must be > 1 hour and ≤ 6 hours for the first lung the second CIT-2 from EVLP cool down to beginning of recipient implantation must be > 1 hour and ≤ 10 hours for the second lung and Study Center Investigator deems lung function suitable for intended subject EVLP Lung Exclusion Criteria for Transplantation: The donor lung is excluded from transplant inclusion if at least one of the following criteria have been met: PvO2/FiO2 < 350 mmHg at final EVLP evaluation time period or ≥ 15% increase from baseline value to final value of pulmonary vascular resistance (PVR) or ≥ 15% increase from baseline value to final value of peak airway pressure (PawP) or ≥ 15% decrease from baseline value to final value of static lung compliance (Cstat) or TPT exceeds any of the following conditions: CIT-1 < 1 hour or > 10 hours EVLP < 3 hours or > 6 hours CIT-2 < 1 hour or > 6 hours for first lung or > 10 hours for second lung or Study Center investigator deems lung function unsuitable for intended subject
Facility Information:
Facility Name
Mayo Clinic Jacksonville
City
Jacksonville
State/Province
Florida
ZIP/Postal Code
32224
Country
United States
Facility Name
Loyola University Medical Center
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60153
Country
United States
Facility Name
University of Maryland Medical Center
City
Baltimore
State/Province
Maryland
ZIP/Postal Code
21201
Country
United States
Facility Name
University of Michigan Health System
City
Ann Arbor
State/Province
Michigan
ZIP/Postal Code
48109
Country
United States
Facility Name
Duke University Health System
City
Durham
State/Province
North Carolina
ZIP/Postal Code
27705
Country
United States
Facility Name
Cleveland Clinic
City
Cleveland
State/Province
Ohio
ZIP/Postal Code
44195
Country
United States
Facility Name
UPMC
City
Pittsburgh
State/Province
Pennsylvania
ZIP/Postal Code
15213
Country
United States
Facility Name
Inova Fairfax Medical Campus
City
Falls Church
State/Province
Virginia
ZIP/Postal Code
22042
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
11882811
Citation
Pierre AF, Sekine Y, Hutcheon MA, Waddell TK, Keshavjee SH. Marginal donor lungs: a reassessment. J Thorac Cardiovasc Surg. 2002 Mar;123(3):421-7; discussion, 427-8. doi: 10.1067/mtc.2002.120345.
Results Reference
background
PubMed Identifier
12241936
Citation
Ware LB, Wang Y, Fang X, Warnock M, Sakuma T, Hall TS, Matthay M. Assessment of lungs rejected for transplantation and implications for donor selection. Lancet. 2002 Aug 24;360(9333):619-20. doi: 10.1016/s0140-6736(02)09774-x.
Results Reference
background
PubMed Identifier
14585380
Citation
Orens JB, Boehler A, de Perrot M, Estenne M, Glanville AR, Keshavjee S, Kotloff R, Morton J, Studer SM, Van Raemdonck D, Waddel T, Snell GI; Pulmonary Council, International Society for Heart and Lung Transplantation. A review of lung transplant donor acceptability criteria. J Heart Lung Transplant. 2003 Nov;22(11):1183-200. doi: 10.1016/s1053-2498(03)00096-2. No abstract available.
Results Reference
background
PubMed Identifier
15699761
Citation
Kawut SM, Reyentovich A, Wilt JS, Anzeck R, Lederer DJ, O'Shea MK, Sonett JR, Arcasoy SM. Outcomes of extended donor lung recipients after lung transplantation. Transplantation. 2005 Feb 15;79(3):310-6. doi: 10.1097/01.tp.0000149504.53710.ae.
Results Reference
background
PubMed Identifier
16210116
Citation
Christie JD, Carby M, Bag R, Corris P, Hertz M, Weill D; ISHLT Working Group on Primary Lung Graft Dysfunction. Report of the ISHLT Working Group on Primary Lung Graft Dysfunction part II: definition. A consensus statement of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 2005 Oct;24(10):1454-9. doi: 10.1016/j.healun.2004.11.049. Epub 2005 Jun 4. No abstract available.
Results Reference
background
PubMed Identifier
16678604
Citation
Botha P, Trivedi D, Weir CJ, Searl CP, Corris PA, Dark JH, Schueler SV. Extended donor criteria in lung transplantation: impact on organ allocation. J Thorac Cardiovasc Surg. 2006 May;131(5):1154-60. doi: 10.1016/j.jtcvs.2005.12.037.
Results Reference
background
PubMed Identifier
17227559
Citation
Avlonitis VS, Wigfield CH, Golledge HD, Kirby JA, Dark JH. Early hemodynamic injury during donor brain death determines the severity of primary graft dysfunction after lung transplantation. Am J Transplant. 2007 Jan;7(1):83-90. doi: 10.1111/j.1600-6143.2006.01593.x.
Results Reference
background
PubMed Identifier
23821506
Citation
Suzuki Y, Cantu E, Christie JD. Primary graft dysfunction. Semin Respir Crit Care Med. 2013 Jun;34(3):305-319. doi: 10.1055/s-0033-1348474. Epub 2013 Jul 2.
Results Reference
background
PubMed Identifier
15162925
Citation
Bennett M, Horton S, Thuys C, Augustin S, Rosenberg M, Brizard C. Pump-induced haemolysis: a comparison of short-term ventricular assist devices. Perfusion. 2004 Mar;19(2):107-11. doi: 10.1191/0267659104pf729oa.
Results Reference
background
PubMed Identifier
17470204
Citation
Watanabe N, Sakota D, Ohuchi K, Takatani S. Deformability of red blood cells and its relation to blood trauma in rotary blood pumps. Artif Organs. 2007 May;31(5):352-8. doi: 10.1111/j.1525-1594.2007.00392.x.
Results Reference
background
PubMed Identifier
19131535
Citation
Lyu DM, Zamora MR. Medical complications of lung transplantation. Proc Am Thorac Soc. 2009 Jan 15;6(1):101-7. doi: 10.1513/pats.200808-077GO.
Results Reference
background
PubMed Identifier
19059112
Citation
Cypel M, Yeung JC, Hirayama S, Rubacha M, Fischer S, Anraku M, Sato M, Harwood S, Pierre A, Waddell TK, de Perrot M, Liu M, Keshavjee S. Technique for prolonged normothermic ex vivo lung perfusion. J Heart Lung Transplant. 2008 Dec;27(12):1319-25. doi: 10.1016/j.healun.2008.09.003.
Results Reference
background
PubMed Identifier
19663886
Citation
Cypel M, Rubacha M, Yeung J, Hirayama S, Torbicki K, Madonik M, Fischer S, Hwang D, Pierre A, Waddell TK, de Perrot M, Liu M, Keshavjee S. Normothermic ex vivo perfusion prevents lung injury compared to extended cold preservation for transplantation. Am J Transplant. 2009 Oct;9(10):2262-9. doi: 10.1111/j.1600-6143.2009.02775.x. Epub 2009 Aug 6.
Results Reference
background
PubMed Identifier
20368171
Citation
Cypel M, Liu M, Rubacha M, Yeung JC, Hirayama S, Anraku M, Sato M, Medin J, Davidson BL, de Perrot M, Waddell TK, Slutsky AS, Keshavjee S. Functional repair of human donor lungs by IL-10 gene therapy. Sci Transl Med. 2009 Oct 28;1(4):4ra9. doi: 10.1126/scitranslmed.3000266.
Results Reference
background
PubMed Identifier
19632569
Citation
Cypel M, Sato M, Yildirim E, Karolak W, Chen F, Yeung J, Boasquevisque C, Leist V, Singer LG, Yasufuku K, Deperrot M, Waddell TK, Keshavjee S, Pierre A. Initial experience with lung donation after cardiocirculatory death in Canada. J Heart Lung Transplant. 2009 Aug;28(8):753-8. doi: 10.1016/j.healun.2009.05.009. Epub 2009 Jun 28.
Results Reference
background
PubMed Identifier
19662970
Citation
Yeung JC, Cypel M, Waddell TK, van Raemdonck D, Keshavjee S. Update on donor assessment, resuscitation, and acceptance criteria, including novel techniques--non-heart-beating donor lung retrieval and ex vivo donor lung perfusion. Thorac Surg Clin. 2009 May;19(2):261-74. doi: 10.1016/j.thorsurg.2009.02.006.
Results Reference
background
PubMed Identifier
21488765
Citation
Cypel M, Yeung JC, Liu M, Anraku M, Chen F, Karolak W, Sato M, Laratta J, Azad S, Madonik M, Chow CW, Chaparro C, Hutcheon M, Singer LG, Slutsky AS, Yasufuku K, de Perrot M, Pierre AF, Waddell TK, Keshavjee S. Normothermic ex vivo lung perfusion in clinical lung transplantation. N Engl J Med. 2011 Apr 14;364(15):1431-40. doi: 10.1056/NEJMoa1014597.
Results Reference
background
PubMed Identifier
21511086
Citation
Cypel M, Yeung JC, Keshavjee S. Novel approaches to expanding the lung donor pool: donation after cardiac death and ex vivo conditioning. Clin Chest Med. 2011 Jun;32(2):233-44. doi: 10.1016/j.ccm.2011.02.003. Epub 2011 Mar 25.
Results Reference
background
PubMed Identifier
21930395
Citation
Koike T, Yeung JC, Cypel M, Rubacha M, Matsuda Y, Sato M, Waddell TK, Liu M, Keshavjee S. Kinetics of lactate metabolism during acellular normothermic ex vivo lung perfusion. J Heart Lung Transplant. 2011 Dec;30(12):1312-9. doi: 10.1016/j.healun.2011.07.014. Epub 2011 Sep 17.
Results Reference
background
PubMed Identifier
22944089
Citation
Cypel M, Yeung JC, Machuca T, Chen M, Singer LG, Yasufuku K, de Perrot M, Pierre A, Waddell TK, Keshavjee S. Experience with the first 50 ex vivo lung perfusions in clinical transplantation. J Thorac Cardiovasc Surg. 2012 Nov;144(5):1200-6. doi: 10.1016/j.jtcvs.2012.08.009. Epub 2012 Aug 31.
Results Reference
background
PubMed Identifier
22975103
Citation
Yeung JC, Cypel M, Machuca TN, Koike T, Cook DJ, Bonato R, Chen M, Sato M, Waddell TK, Liu M, Slutsky AS, Keshavjee S. Physiologic assessment of the ex vivo donor lung for transplantation. J Heart Lung Transplant. 2012 Oct;31(10):1120-6. doi: 10.1016/j.healun.2012.08.016.
Results Reference
background
PubMed Identifier
23009140
Citation
Wigfield CH, Cypel M, Yeung J, Waddell T, Alex C, Johnson C, Keshavjee S, Love RB. Successful emergent lung transplantation after remote ex vivo perfusion optimization and transportation of donor lungs. Am J Transplant. 2012 Oct;12(10):2838-44. doi: 10.1111/j.1600-6143.2012.04175.x.
Results Reference
background
PubMed Identifier
22283576
Citation
Cypel M, Keshavjee S. The clinical potential of ex vivo lung perfusion. Expert Rev Respir Med. 2012 Feb;6(1):27-35. doi: 10.1586/ers.11.93.
Results Reference
background
PubMed Identifier
24429157
Citation
Munshi L, Keshavjee S, Cypel M. Donor management and lung preservation for lung transplantation. Lancet Respir Med. 2013 Jun;1(4):318-28. doi: 10.1016/S2213-2600(12)70064-4. Epub 2013 Feb 20.
Results Reference
background
PubMed Identifier
36229329
Citation
Mallea JM, Hartwig MG, Keller CA, Kon Z, Iii RNP, Erasmus DB, Roberts M, Patzlaff NE, Johnson D, Sanchez PG, D'Cunha J, Brown AW, Dilling DF, McCurry K. Remote ex vivo lung perfusion at a centralized evaluation facility. J Heart Lung Transplant. 2022 Dec;41(12):1700-1711. doi: 10.1016/j.healun.2022.09.006. Epub 2022 Sep 18.
Results Reference
derived

Learn more about this trial

Extending Preservation and Assessment Time of Donor Lungs Using the Toronto EVLP System™ at a Dedicated EVLP Facility

We'll reach out to this number within 24 hrs